Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iradimed (IRMD) Total Liabilities (2016 - 2025)

Iradimed (IRMD) has disclosed Total Liabilities for 13 consecutive years, with $14.2 million as the latest value for Q4 2025.

  • Quarterly Total Liabilities rose 23.04% to $14.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $14.2 million through Dec 2025, up 23.04% year-over-year, with the annual reading at $14.2 million for FY2025, 23.04% up from the prior year.
  • Total Liabilities for Q4 2025 was $14.2 million at Iradimed, down from $16.4 million in the prior quarter.
  • The five-year high for Total Liabilities was $20.7 million in Q4 2023, with the low at $9.1 million in Q1 2021.
  • Average Total Liabilities over 5 years is $11.9 million, with a median of $11.4 million recorded in 2023.
  • The sharpest move saw Total Liabilities soared 75.12% in 2023, then tumbled 44.51% in 2024.
  • Over 5 years, Total Liabilities stood at $10.7 million in 2021, then rose by 10.58% to $11.8 million in 2022, then skyrocketed by 75.12% to $20.7 million in 2023, then crashed by 44.51% to $11.5 million in 2024, then rose by 23.04% to $14.2 million in 2025.
  • According to Business Quant data, Total Liabilities over the past three periods came in at $14.2 million, $16.4 million, and $12.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.